Results 201 to 210 of about 203,270 (263)

Refining the adriamycin‐induced focal segmental glomerulosclerosis mouse model to improve reproducibility and animal welfare

Animal Models and Experimental Medicine, EarlyView.
This study suggested the instability of Adriamycin (ADR) in aqueous solution as the main contributor to large ADR dose variations in literature of the ADR‐induced mouse model of focal segmental glomerulosclerosis (FSGS). We confirmed that freshly prepared ADR solution dosed at 10.5 mg/kg to be optimal in reliably producing FSGS pathology in BALB/c mice
Haochen Jiang, Salma Althobaiti, Braeden Pinkerton, Xin Fu, Zhenshan Jia, Kirk W. Foster, Geoffrey M. Thiele, Troy J. Plumb, Dong Wang   +8 more
wiley   +1 more source

Prospective study of live attenuated vaccines for patients receiving immunosuppressive agents. [PDF]

PLoS One, 2020
Kamei K, Miyairi I, Ishikura K, Ogura M, Shoji K, Arai K, Ito R, Kawai T, Ito S.   +8 more
europepmc   +1 more source

Roadmap to Nanomedical Applications: Nanotoxicology and In Vitro Guidelines for Lanthanide‐Doped Luminescence Nanothermometers

Advanced NanoBiomed Research, EarlyView.
Lanthanide‐based luminescence nanothermometry holds multifaceted potential for nanomedical applications, yet despite significant research advances, clinical translation of the engineered nanomaterials is still controversial and widely disputed. This is related to crucial nanotoxicological aspects that must be addressed at the preclinical level ...
Simona Premcheska, Andre G. Skirtach, Anna M. Kaczmarek   +2 more
wiley   +1 more source

Recent Advances in Cancer Cell Membrane‐Based Nanoparticles and Cancer Cell‐Derived Small Extracellular Vesicles as Drug Delivery Platforms

Advanced NanoBiomed Research, EarlyView.
Cancer cell membrane‐based nanoparticles (CCM‐NPs) and cancer cell‐derived small extracellular vesicles (CsEVs) are emerging as promising drug delivery systems for targeted cancer treatment. Advances in nanotechnology have paved the way for innovative drug delivery systems that enhance the effectiveness of cancer treatment.
Wei Zhang, Jingjing Wang, Long Ngo, Li Li, Yuling Wang   +4 more
wiley   +1 more source

COVID-19 in rheumatic disease patients on immunosuppressive agents. [PDF]

Semin Arthritis Rheum, 2020
Sharmeen S, Elghawy A, Zarlasht F, Yao Q.   +3 more
europepmc   +1 more source

Immunosuppressive agents for rheumatoid arthritis: a systematic review of clinical trials and their current development stage. [PDF]

Ther Adv Musculoskelet Dis, 2020
Blaess J, Walther J, Petitdemange A, Gottenberg JE, Sibilia J, Arnaud L, Felten R.   +6 more
europepmc   +1 more source

Efficacy and Safety of Subcutaneous Abatacept Plus Standard Treatment for Active Idiopathic Inflammatory Myopathy: Phase 3 Randomized Controlled Trial

Arthritis &Rheumatology, EarlyView.
Objective Our objective was to evaluate the efficacy and safety of subcutaneous (SC) abatacept and standard of care (SOC) for the treatment of idiopathic inflammatory myopathy (IIM) over 52 weeks. Methods In this randomized, double‐blind, placebo‐controlled phase III trial, patients with treatment‐refractory IIM received SC abatacept (at 125 mg weekly)
Rohit Aggarwal, Ingrid E. Lundberg, Yeong‐Wook Song, Aziz Shaibani, Victoria P. Werth, Michael A. Maldonado   +5 more
wiley   +1 more source

Drug Interactions between Antimicrobial and Immunosuppressive Agents in Solid Organ Transplant Recipients.

Indian J Crit Care Med, 2021
Bhagat V, Pandit RA, Ambapurkar S, Sengar M, Kulkarni AP.   +4 more
europepmc   +1 more source

Evaluating Renal Disease in Pediatric‐Onset Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: Disease Course, Outcomes, and Predictors of Outcome

Arthritis &Rheumatology, EarlyView.
Objective We aimed to study the disease course, outcomes, and predictors of outcome in pediatric‐onset antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV) affecting the kidneys. Methods Patients eligible for this study had a diagnosis of granulomatosis with polyangiitis (GPA), microscopic polyangiitis, or ANCA‐positive pauci‐immune ...
Kirandeep K. Toor, Audrea Chen, David A. Cabral, Cherry Mammen, Else S. Bosman, Ye Shen, Jeffrey N. Bone, Damien Noone, Eslam Al‐Abadi, Susanne Benseler, Roberta Berard, Marek Bohm, Sirirat Charuvanij, Kathryn Cook, Paul Dancey, Samundeeswari Deepak, Ciaran Duffy, Barbara Eberhard, Melissa Elder, Dirk Foell, Dana Gerstbacher, Merav Heshin‐Bekenstein, Adam Huber, Karen E. James, Susan Kim, Marisa Klein‐Gitelman, Neil Martin, Flora McErlane, L. Nandini Moorthy, Charlotte Myrup, Phil Riley, Susan Shenoi, Vidya Sivaraman, Tamara Tanner, Stacey Tarvin, Linda Wagner‐Weiner, Rae S. M. Yeung, Kelly L. Brown, Kimberly A. Morishita, on behalf of the PedVas Investigators Network   +39 more
wiley   +1 more source

Immediate Therapeutic Response to Vigabatrin in Lissencephaly‐Related Epileptic Spasms due to TUBA1A R402H Variant

American Journal of Medical Genetics Part A, EarlyView.
Toru Nagata, Takashi Shibata, Hiroki Tsuchiya, Mari Akiyama, Mitsuhiro Kato, Tomoyuki Akiyama, Toshiki Takenouchi   +6 more
wiley   +1 more source